Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Vagus nerve stimulation and other neuromodulation
9 evidence topics · 11 sources
CANMAT guideline: VNS third-line, DBS investigational
“To date, there are very few RCTs involving VNS, and these studies have failed to demonstrate the efficacy of VNS compared to sham control conditions in the short term.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“VNS is generally safe and well tolerated, with the most common side effects involving pain related to device implantation, voice hoarseness or alteration (due to intermittent stimulation of the larynx), coughing, headache, sore throat, and neck pain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, VNS is the only surgical neuromodulation treatment approved for TRD by regulatory agencies and is recommended as a third-line option” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DBS and MST are currently considered investigational due to limited available evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VA/DoD guideline: against VNS and DBS outside research
NICE interventional procedures guidance on implanted VNS
Medicare coverage of VNS limited to coverage with evidence development
RECOVER: 12-month sham-controlled trial
“This 12-month, multicenter, double-blind, sham-controlled trial included 493 adults with marked treatment-resistant major depression who were randomized to active or no-stimulation sham VNS for 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Percent time in MADRS response did not distinguish active from sham VNS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Active VNS exceeded sham VNS in rate of dyspnea (P = 0.035), a known side effect of VNS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
RECOVER: quality of life and function
“Active VNS was superior to sham in mean change in scores from baseline in the Mini-Q-LES-Q (P = 0.050) and WPAI item 6 (health condition's effect on regular activities [P = 0.050]) used as continuous variables, with a similar trend for Q-LES-Q (P = 0.061).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
RECOVER: durability of benefit over 24 months
“Prospective, open-label, single-arm, long-term extension study (RECOVER) conducted from September 2019 to April 2025.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Depressive symptom, daily function, and QoL benefits obtained after 12 months of adjunctive VNS were sustained in about 80% of participants continuing VNS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It did not demonstrate that VNS was necessary in achieving this sustained benefit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conducting the study was also supported by the Centers for Medicare & Medicaid Services.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Five-year registry: adjunctive VNS compared with treatment as usual
“This 5-year, prospective, open-label, nonrandomized, observational registry study was conducted at 61 U.S. sites and included 795 patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The registry results indicate that the adjunctive VNS group had better clinical outcomes than the treatment-as-usual group, including a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Deep brain stimulation of the ventral anterior limb of the internal capsule
“Following the optimization phase, which lasted 51.6 (22.0) weeks, 10 patients (40%) were classified as responders and 15 individuals (60%) as nonresponders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During active DBS, patients scored significantly lower on the HAM-D-17 scale (13.6 [95% CI, 9.8-17.4]) than during sham DBS (23.1 [95% CI, 20.6-25.6]) (P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Serious adverse events included severe nausea during surgery (1 patient), suicide attempt (4 patients), and suicidal ideation (2 patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote